COMPRO (prochlorperazine) by Design Pharmaceuticals is clinical pharmacology prochlorperazine is a propylpiperazine derivative of phenothiazine. Approved for the control of severe nausea, vomiting in adults. First approved in 2000.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Prochlorperazine is a propylpiperazine derivative of phenothiazine. Like other phenothiazines, it exerts an antiemetic effect through a depressant action on the chemoreceptor trigger zone.
Phenothiazine
Worked on COMPRO at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function
Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons
Clinical Study Protocol for Cutaneous SCC for Immunocompromised Patients
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo